Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olanzapine + zuclopenthixol + risperidone + pipotiazine + quetiapine + flupentixol
- Development stage
- Unknown
- Lead developer
- Strasbourg University Hospital
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
This entry refers to a group of first-generation and second-generation antipsychotic medications utilized in the DREAMS-Phen clinical trial (NCT04718311) sponsored by the University Hospital of Strasbourg. The study evaluates two treatment strategies—dose reduction versus maintenance treatment—in patients stabilized from schizophrenia spectrum disorders, stratified by their psychotic phenotype (cycloid vs. non-cycloid). The medications included in this group represent a mix of atypical antipsychotics (olanzapine, risperidone, quetiapine) and typical antipsychotics (zuclopenthixol, pipotiazine, flupentixol), which primarily function through the antagonism of dopamine D2 and serotonin 5-HT2A receptors to manage positive and negative symptoms of psychosis.
- Other names
- olanzapine + zuclopenthixol + risperidone + pipotiazine + quetiapine + flupentixolDREAMS-Phen antipsychotics
02
Targets
HTR2A (Serotonin receptor 5-HT2A)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on olanzapine + zuclopenthixol + risperidone + pipotiazine + quetiapine + flupentixol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olanzapine + zuclopenthixol + risperidone + pipotiazine + quetiapine + flupentixol.